Skip to main content

Table 2 Subgroup analyses of response rate

From: The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis

prognostic factor events n I2 response rate(%) 95%CL Q p
Overall 125 178 0.584 67 53–79   
Ag recognition moieties
 CD19 118 169 62.6% 66 50–79   
 CD20 7 9 0% 70 39–89 0.05 0.8187
Disease
 leukemia 90 125 50.3% 68 53–80   
 lymphoma 35 53 53.8% 61 53–77 0.21 0.6482
T cell origin
 Autologous 116 157 53.9% 71 56–82   
 Allogeneic 9 21 50.7% 46 17–78 1.74 0.1873
Generation
 1st 8 12 73% 61 7–97   
 2nd 116 159 55.7% 69 56–80 0.07 0.7928
costimulatory domains
 CD137 and CD3ζ 49 63 36.1% 73 60–83   
 CD28 and CD3ζ 68 101 59.9% 65 45–80 0.52 0.4715
T cell activation
 OKT3 86 105 42% 77 67–85   
 CD3/CD28 beads 29 51 58% 56 31–79 2.91 0.0882
IL-2 administration to cells
 yes 42 75 67.5% 51 28–75   
 no 78 97 17.9% 77 65–85 3.62 0.057
Transfection methods
 non-viral vector 2 5 4% 42 12–79   
 viral vector 123 173 61% 69 54–80 1.41 0.2345
Lymphodepletion
 yes 98 127 34.1% 72 63–80   
 no 15 38 42.1% 44 28–62 4.2 0.0405
CART cells
 ≥ 108 83 109 50.5% 72 56–84   
 < 108 36 50 6.5% 66 52–78 0.31 0.5782
IL-2 administration to patients
 yes 9 11 0% 72 44–90   
 no 122 167 67.9% 67 49–81 0.12 0.7293
T cell persistence time
 ≥ 2 months 92 117 0% 74 65–81   
 < 2 months 34 60 56.4% 50 27–73 3.59 0.0581
Peak serum IL-2 level
 ≥ 50 pg/mL 11 12 0% 85 55–96   
 < 50 pg/mL 5 16 56.6% 31 6–74 4.22 0.04